semaxanib
A quinolone derivative with potential antineoplastic activity. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells.
| Synonym: | semoxind |
|---|---|
| Code name: | SU5416 Sugen 5416 |
| Chemical structure: | 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one H-indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro- |